DA Davidson Trims USANA Health Sciences (NYSE:USNA) Target Price to $35.00

USANA Health Sciences (NYSE:USNA) had its price objective dropped by research analysts at DA Davidson from $38.00 to $35.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. DA Davidson’s price target indicates a potential upside of 1.45% from the stock’s previous close.

Separately, StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.

USANA Health Sciences Stock Down 1.6 %

USANA Health Sciences stock opened at $34.50 on Wednesday. The firm has a market cap of $657.26 million, a P/E ratio of 10.75, a P/E/G ratio of 1.20 and a beta of 0.89. The business has a fifty day moving average of $38.02 and a two-hundred day moving average of $42.59. USANA Health Sciences has a twelve month low of $34.15 and a twelve month high of $56.02.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.11). The company had revenue of $212.87 million during the quarter, compared to analysts’ expectations of $218.64 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same quarter last year, the firm earned $0.89 EPS. Equities analysts expect that USANA Health Sciences will post 2.5 earnings per share for the current year.

Insider Buying and Selling at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 674 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total transaction of $26,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other USANA Health Sciences news, Director Gilbert A. Fuller sold 674 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul A. Jones sold 6,266 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,940 shares of company stock worth $311,670. Company insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On USANA Health Sciences

Hedge funds have recently modified their holdings of the company. DGS Capital Management LLC lifted its position in shares of USANA Health Sciences by 61.8% during the 1st quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock valued at $352,000 after buying an additional 2,773 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of USANA Health Sciences by 18.1% in the first quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company’s stock worth $1,883,000 after acquiring an additional 5,952 shares during the last quarter. Pzena Investment Management LLC increased its position in shares of USANA Health Sciences by 3.1% during the first quarter. Pzena Investment Management LLC now owns 785,344 shares of the company’s stock worth $38,089,000 after purchasing an additional 23,729 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of USANA Health Sciences by 22.7% in the first quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock valued at $409,000 after buying an additional 1,560 shares during the last quarter. Finally, BOKF NA boosted its position in USANA Health Sciences by 274.5% during the first quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after acquiring an additional 2,031 shares during the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.